SPOTLIGHT: Callisto restructures Atiprimod deal

Callisto Pharmaceuticals has restructured its license agreement with Genzyme for Atiprimod, Callisto's lead drug to treat advanced carcinoid cancer. The new agreement eliminates all milestone payments and reduces royalties owed to Genzyme. In return for the reduced future payments to Genzyme, Callisto is paying an upfront fee in 2008. "This restructured licensing agreement significantly improves the potential economic upside value for Atiprimod and puts us in a stronger position to further develop and commercialize the product," said Gabriele M. Cerrone, chairman of Callisto. "We recently completed enrollment in our Atiprimod Phase II trial in advanced carcinoid cancer patients and we expect to complete an interim analysis of the data by the end of the first quarter of this year. We believe this new agreement with Genzyme will provide substantial help in obtaining financing for a potential Phase III trial." Release

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

The data position Leo to file for approval of the Dupixent rival in atopic dermatitis next year.